Registry development for patients with gynecologic cancer in Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect and analyze data on the characteristics, treatment trends, prognostic factors, and survival outcomes of patients with gynecologic cancers such as cervical, endometrial, and ovarian cancer in Korea. By gathering both retrospective and prospective medical information, the study seeks to address critical issues related to surgical methods, disease recurrence, and overall survival in real-world settings. The ultimate goal is to enhance treatment strategies and improve patient survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients 18 years or older
* Written informed consent (prospective cohort)
* Confirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Exclusion Criteria:

* Unconfirmed diagnosis of cervical cancer, endometrial cancer or ovarian cancer

Where it's running

• Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
  Seoul, South Korea Recruiting

Study contacts

• Principal investigator: Jeong-Yeol Park, PhD — Asan Medical Center
• Study coordinator: Jeong-Yeol Park, PhD
• Email: obgyjypark@amc.seoul.kr
• Phone: +82230103646

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Comparing two types of sutures for vaginal cuff closure in laparoscopic hysterectomy

  This study is testing whether a new type of suture can close the vaginal cuff faster than a standard suture for women having laparoscopic hysterectomy, without causing more complications.

  Recruiting at 2 sites Aesculap AG · Frankfurt am Main, Hesse and 1 other locations · NCT06024109

• Collecting specimens and data for early detection and prevention of ovarian cancer

  This study is trying to find better ways to detect and prevent ovarian cancer early by collecting blood and tissue samples from people at high risk.

  Recruiting Northwestern University · Chicago, Illinois · NCT00005095

• Stellate ganglion block and dexmedetomidine for better sleep after gynecologic laparoscopy

  The study tests whether giving a preoperative stellate ganglion block plus intraoperative dexmedetomidine improves sleep after laparoscopic gynecologic surgery in women.

  Recruiting The Second People's Hospital of Huai'an · Huai'an, Jiangsu · NCT07860203

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.